COX-2 Selective Nonsteroidal Anti-Inflammatory Drugs

[1]  C. Hawkey,et al.  Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa , 2000, Gut.

[2]  P. Isakson,et al.  Effects of Celecoxib, a Novel Cyclooxygenase‐2 Inhibitor, on Platelet Function in Healthy Adults: A Randomized, Controlled Trial , 2000, Journal of clinical pharmacology.

[3]  C. Hawkey,et al.  Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. , 2000, Arthritis and rheumatism.

[4]  P. Isakson,et al.  Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison , 1999, The Lancet.

[5]  J. Bolognese,et al.  Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. , 1999, JAMA.

[6]  D. Graham,et al.  Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. , 1999, JAMA.

[7]  B. Cryer,et al.  COX-1-sparing NSAIDs--is the enthusiasm justified? , 1999, JAMA.

[8]  J. Palmer,et al.  Intracellular gene transfer in action: dual transcription and multiple silencings of nuclear and mitochondrial cox2 genes in legumes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[9]  T. Schnitzer,et al.  Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group. , 1999, The Journal of rheumatology.

[10]  P. Isakson,et al.  Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. , 1999, Mayo Clinic proceedings.

[11]  L. Laine,et al.  A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. , 1999, Gastroenterology.

[12]  S. Daniels,et al.  Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial. , 1999, Clinical therapeutics.

[13]  H Perrier,et al.  Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. , 1999, The Journal of pharmacology and experimental therapeutics.

[14]  R. Lorenz,et al.  Cyclooxygenase-2-dependent arachidonic acid metabolites are essential modulators of the intestinal immune response to dietary antigen , 1999, Nature Medicine.

[15]  J. Vane,et al.  Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[16]  K. Seibert,et al.  COX-2 Inhibitors – Is there cause for concern? , 1999, Nature Medicine.

[17]  J. Bolognese,et al.  Specific inhibition of cyclooxygenase‐2 with MK‐0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen , 1999, Alimentary pharmacology & therapeutics.

[18]  D. Gilroy,et al.  Inducible cyclooxygenase may have anti-inflammatory properties , 1999, Nature Medicine.

[19]  W. Yuan,et al.  Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial. , 1999, Clinical therapeutics.

[20]  G. FitzGerald,et al.  Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. , 1999, The Journal of pharmacology and experimental therapeutics.

[21]  R. Hall,et al.  Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[22]  D. Riendeau,et al.  Characterization of rofecoxib as a cyclooxygenase‐2 isoform inhibitor and demonstration of analgesia in the dental pain model , 1999, Clinical pharmacology and therapeutics.

[23]  M. Breyer.  COX2 selective NSAIDs and renal function: gain without pain? , 1999, Kidney international.

[24]  G. FitzGerald,et al.  Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[25]  R. Hunt,et al.  Guidelines for the management of Helicobacter pylori infection , 1998, American Journal of Gastroenterology.

[26]  K. Takeuchi,et al.  Effects of Cyclooxygenase-2 Selective and Nitric Oxide-Releasing Nonsteroidal Antiinflammatory Drugs on Mucosal Ulcerogenic and Healing Responses of the Stomach , 1998, Digestive Diseases and Sciences.

[27]  P. Lipsky,et al.  Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. , 1998, Arthritis and rheumatism.

[28]  C. Hawkey,et al.  Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. , 1998, British journal of rheumatology.

[29]  C. Hawkey,et al.  Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. , 1998, British journal of rheumatology.

[30]  P. Aisen,et al.  Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain , 1998, Neuroscience.

[31]  P. Netzer,et al.  Effects of inhibition of prostaglandin endoperoxide synthase‐2 in chronic gastro‐intestinal ulcer models in rats , 1998, British journal of pharmacology.

[32]  L. G. García Rodríguez,et al.  Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. , 1998, Archives of internal medicine.

[33]  C. Patrono,et al.  Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. , 1997, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[34]  A. Sousa,et al.  Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma. , 1997, Thorax.

[35]  J. Pepper,et al.  Induction of cyclooxygenase-2 in human saphenous vein and internal mammary artery. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[36]  P. Lipsky,et al.  Outcome of specific COX-2 inhibition in rheumatoid arthritis. , 1997, The Journal of rheumatology. Supplement.

[37]  J. Falgueyret,et al.  Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX‐2 inhibitor , 1997, British journal of pharmacology.

[38]  J. Wallace.  Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. , 1997, Gastroenterology.

[39]  G. Levy.  Prostaglandin H synthases, nonsteroidal antiinflammatory drugs, and colon cancer , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[40]  E. Delevaque,et al.  Influence of H/sub 2/ loading on the kinetics of Type IIA fibre Bragg grating photoinscription , 1997 .

[41]  M. Kasuga,et al.  Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. , 1997, Gastroenterology.

[42]  J. Wallace,et al.  Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. , 1996, The Journal of clinical investigation.

[43]  J. Chow,et al.  Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2 , 1996, Nature Structural Biology.

[44]  Patrick L. McGeer,et al.  Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease , 1996, Neurology.

[45]  J. Gierse,et al.  A Single Amino Acid Difference between Cyclooxygenase-1 (COX-1) and −2 (COX-2) Reverses the Selectivity of COX-2 Specific Inhibitors* , 1996, The Journal of Biological Chemistry.

[46]  J. Young,et al.  Human whole blood assays for inhibition of prostaglandin G/H synthases-1 and-2 using A23187 and lipopolysaccharide stimulation of thromboxane B2 production , 1996, Inflammation Research.

[47]  M. Marini,et al.  A 4-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers. , 1996, British journal of rheumatology.

[48]  J. Fries,et al.  Safety of meloxicam: a global analysis of clinical trials. , 1996, British journal of rheumatology.

[49]  J. Wallace,et al.  Nitric oxide as a mediator of gastrointestinal mucosal injury?—Say it ain't so , 1995, Mediators of inflammation.

[50]  A. Bennett,et al.  Activity of nimesulide on constitutive and inducible cyclooxygenases. , 1995, Arzneimittel-Forschung.

[51]  J. Wallace,et al.  A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. , 1995, Gastroenterology.

[52]  C. Hawkey.  Future treatments for arthritis: new NSAIDs, NO NSAIDs, or no NSAIDs? , 1995, Gastroenterology.

[53]  K. Glaser,et al.  Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. , 1995, European journal of pharmacology.

[54]  S. Iacobelli,et al.  Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. , 1994, The Journal of pharmacology and experimental therapeutics.

[55]  H. Jacobson,et al.  Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. , 1994, The Journal of clinical investigation.

[56]  R. N. Brogden,et al.  Erratum to: Nimesulide: an update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy , 1994, Drugs.

[57]  P. Loll,et al.  The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1 , 1994, Nature.

[58]  B. Whittle.  Neuronal and endothelium‐derived mediators in the modulation of the gastric microcirculation: integrity in the balance , 1993, British journal of pharmacology.

[59]  C. Torrance,et al.  Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. , 1992, The New England journal of medicine.

[60]  J. Wallace.  Gastroduodenal mucosal defense , 1991 .

[61]  J. Balfour,et al.  Etodolac. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases and pain states. , 1991, Drugs.

[62]  B. Varnum,et al.  TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. , 1991, The Journal of biological chemistry.

[63]  K. Seibert,et al.  The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. , 1990, The Journal of biological chemistry.

[64]  C. Hawkey.  Non-steroidal anti-inflammatory drugs and peptic ulcers. , 1990, BMJ.

[65]  D. Levy,et al.  Identification of a phorbol ester-repressible v-src-inducible gene. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[66]  H. Kaufmann,et al.  Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. , 1987, Annals of internal medicine.

[67]  M. Sanda,et al.  An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa. , 1987, The Journal of rheumatology.

[68]  C. Hawkey.  Evidence that prednisolone is inhibitory to the cyclooxygenase activity of human rectal mucosa. , 1982 .

[69]  J. Vane,et al.  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.

[70]  G. Vignon.  [Treatment of osteoarthritis of the knee]. , 1954, Le Progres medical.

[71]  R. Russell.  Endoscopic evaluation of etodolac and naproxen, and their relative effects on gastric and duodenal prostaglandins , 2005, Rheumatology International.

[72]  Description.  VIOXX ® ( rofecoxib tablets and oral suspension ) , 2003 .

[73]  E. Boyce,et al.  Celecoxib: A COX-2 inhibitor for the treatment of osteoarthritis and rheumatoid arthritis , 1999 .

[74]  D. Türck,et al.  Differential inhibition of COX-1 and COX-2 by NSAIDs: a summary of results obtained using various test systems , 1998 .

[75]  C. Koboldt,et al.  Specific COX-2 inhibitors: from bench to bedside , 1998 .

[76]  R. Holder,et al.  The acute phase and function in early rheumatoid arthritis. C-reactive protein levels correlate with functional outcome. , 1997, The Journal of rheumatology.

[77]  L. Churchill,et al.  Differential inhibition of cyclooxygenases 1 and 2 by NSAIDs , 1996 .

[78]  R. N. Brogden,et al.  Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. , 1994, Drugs.

[79]  J. Case,et al.  In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. , 1992, The Journal of clinical investigation.